Biological E (BE), a Hyderabad-based vaccine and pharmaceutical company, has recently announced the publication of CORBEVAX COVID-19 vaccine phase II/III clinical trials conducted in paediatric population (5 to <18 age group). 

The vaccine has demonstrated excellent safety profile in children and adolescents. The vaccine also demonstrated excellent immunogenicity as measured by humoral and cellular immune responses. 

Dr Vikram Paradkar, Executive Vice President-Technical Operations, Biological E. Limited, said, “CORBEVAX getting approved for our paediatric population from 5 to 18 age-group was a major milestone for us and its subsequent Pan-India deployment for kids of 12-14 years was important in our fight against coronavirus. So far, approximately 74 million doses of CORBEVAX has been administered to kids in India and almost 33 million kids have completed two-dose primary vaccination, which represents one of the largest paediatric campaigns globally.  We plan to eventually test the vaccine on infants as young as six months, based on the excellent safety record and consistent immunogenicity observed in paediatric trials and deployment."

In August, CORBEVAX became the first vaccine in India to get DCGI approval for a COVID-19 heterologous booster shot. It can be administered six months after two doses of COVISHIELD or COVAXIN for all adults.